罗米波司汀、小剂量利妥昔单抗和大剂量地塞米松治疗新诊断的免疫性血小板减少症：试点研究。

IF 5.1 2区医学 Q1 HEMATOLOGY British Journal of Haematology Pub Date : 2024-11-24 DOI:10.1111/bjh.19923

Perla R Colunga-Pedraza, Fernando De la Garza-Salazar, Héctor A Vaquera-Alfaro, Andrés Gómez-De León, Mónica Bustillos-Muñoz, Luz Tarín-Arzaga, Olga Cantú-Rodríguez, César Homero Gutiérrez-Aguirre, David Gómez-Almaguer

{"title":"罗米波司汀、小剂量利妥昔单抗和大剂量地塞米松治疗新诊断的免疫性血小板减少症：试点研究。","authors":"Perla R Colunga-Pedraza, Fernando De la Garza-Salazar, Héctor A Vaquera-Alfaro, Andrés Gómez-De León, Mónica Bustillos-Muñoz, Luz Tarín-Arzaga, Olga Cantú-Rodríguez, César Homero Gutiérrez-Aguirre, David Gómez-Almaguer","doi":"10.1111/bjh.19923","DOIUrl":null,"url":null,"abstract":"Therapies such as corticosteroids, thrombopoietin receptor agonists and immunomodulators have been consistently under the spotlight in the search for a better treatment for immune thrombocytopenia (ITP). However, none of them has been widely embraced as a new standard. In this pilot study, we investigated feasibility, safety and preliminary efficacy of romiplostim, low-dose rituximab and high-dose dexamethasone for newly diagnosed ITP. We conducted a single-centre single-arm pilot. One-month treatment adherence was 100%. The 1-month overall response rate was 92.3%. Complete response occurred in 11 (84.6%) patients. Median duration of response was 4.13 monts (range 0.2-25). No serious adverse events presented.","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":5.1000,"publicationDate":"2024-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Romiplostim, low-dose rituximab and high-dose dexamethasone for newly diagnosed immune thrombocytopenia: A pilot study.\",\"authors\":\"Perla R Colunga-Pedraza, Fernando De la Garza-Salazar, Héctor A Vaquera-Alfaro, Andrés Gómez-De León, Mónica Bustillos-Muñoz, Luz Tarín-Arzaga, Olga Cantú-Rodríguez, César Homero Gutiérrez-Aguirre, David Gómez-Almaguer\",\"doi\":\"10.1111/bjh.19923\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Therapies such as corticosteroids, thrombopoietin receptor agonists and immunomodulators have been consistently under the spotlight in the search for a better treatment for immune thrombocytopenia (ITP). However, none of them has been widely embraced as a new standard. In this pilot study, we investigated feasibility, safety and preliminary efficacy of romiplostim, low-dose rituximab and high-dose dexamethasone for newly diagnosed ITP. We conducted a single-centre single-arm pilot. One-month treatment adherence was 100%. The 1-month overall response rate was 92.3%. Complete response occurred in 11 (84.6%) patients. Median duration of response was 4.13 monts (range 0.2-25). No serious adverse events presented.\",\"PeriodicalId\":135,\"journal\":{\"name\":\"British Journal of Haematology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":5.1000,\"publicationDate\":\"2024-11-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"British Journal of Haematology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/bjh.19923\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Journal of Haematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/bjh.19923","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

在寻找更好的免疫性血小板减少症（ITP）治疗方法的过程中，皮质类固醇、血小板生成素受体激动剂和免疫调节剂等疗法一直备受关注。然而，没有一种药物被广泛接受为新标准。在这项试验性研究中，我们对罗米波司汀、小剂量利妥昔单抗和大剂量地塞米松治疗新诊断的ITP的可行性、安全性和初步疗效进行了调查。我们进行了一项单中心单臂试验。一个月的治疗依从性为100%。1个月的总体应答率为92.3%。11例（84.6%）患者出现完全应答。中位应答持续时间为 4.13 个月（0.2-25 个月）。无严重不良事件发生。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Romiplostim, low-dose rituximab and high-dose dexamethasone for newly diagnosed immune thrombocytopenia: A pilot study.

Therapies such as corticosteroids, thrombopoietin receptor agonists and immunomodulators have been consistently under the spotlight in the search for a better treatment for immune thrombocytopenia (ITP). However, none of them has been widely embraced as a new standard. In this pilot study, we investigated feasibility, safety and preliminary efficacy of romiplostim, low-dose rituximab and high-dose dexamethasone for newly diagnosed ITP. We conducted a single-centre single-arm pilot. One-month treatment adherence was 100%. The 1-month overall response rate was 92.3%. Complete response occurred in 11 (84.6%) patients. Median duration of response was 4.13 monts (range 0.2-25). No serious adverse events presented.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

British Journal of Haematology 医学-血液学

CiteScore

8.60

自引率

4.60%

发文量

565

审稿时长

1 months

期刊介绍： The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.